CorMedix (CRMD) Misses Q4 EPS by 69c
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Join SI Premium – FREE
CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.16, $0.69 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.48 million.
For earnings history and earnings-related data on CorMedix (CRMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Lyntris opens at $15.50, below IPO price of $17.50
- Stripe agrees to acquire AI model routing platform OpenRouter
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
